MedTrace Logo

An Interventional Left Ventricular Assist System for Cardiogenic Shock

NCT06127927 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-07-08

No results posted yet for this study

Summary

Imported Impella The price is relatively expensive and difficult for ordinary patients to afford. In order to better meet the growing clinical needs in China, Anhui Tongling Bionic Technology Co., Ltd. has developed an interventional left ventricular assist system. The test device was tested in preclinical animals It has shown good effectiveness and safety. Through the implementation of this clinical trial, the interventional left ventricular assist system The safety and effectiveness of the system for hemodynamic support in patients with cardiogenic shock have led to further development of this product in the country.

Conditions

  • Cardiogenic Shock

Interventions

DEVICE

Interventional Left Ventricular Assist System

Interventional left ventricular assist system for cardiogenic shock patients

Sponsors & Collaborators

  • Fujian Medical University

    lead OTHER

Principal Investigators

  • Liang-wan Chen, M.D Ph.D · Fujian Medical University Union Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-08
Primary Completion
2025-11-08
Completion
2025-12-08

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06127927 on ClinicalTrials.gov